TY - JOUR
T1 - Progress in molecular-based management of differentiated thyroid cancer
AU - Xing, Mingzhao
AU - Haugen, Bryan R.
AU - Schlumberger, Martin
N1 - Funding Information:
The authors’ effort for this manuscript is supported by the United States National Institutes of Health grants R01CA134225 and R01CA113507 to MX; Mary Rossick Kern and Jerome H Kern endowment for BRH; and a grant from the French National Cancer Institute to MS.
PY - 2013/3
Y1 - 2013/3
N2 - Substantial developments have occurred in the past 5-10 years in clinical translational research of thyroid cancer. Diagnostic molecular markers, such as RET-PTC, RAS, and BRAFV600E mutations; galectin 3; and a new gene expression classifier, are outstanding examples that have improved diagnosis of thyroid nodules. BRAF mutation is a prognostic genetic marker that has improved risk stratification and hence tailored management of patients with thyroid cancer, including those with conventionally low risks. Novel molecular-targeted treatments hold great promise for radioiodine-refractory and surgically inoperable thyroid cancers as shown in clinical trials; such treatments are likely to become a component of the standard treatment regimen for patients with thyroid cancer in the near future. These novel molecular-based management strategies for thyroid nodules and thyroid cancer are the most exciting developments in this unprecedented era of molecular thyroid-cancer medicine.
AB - Substantial developments have occurred in the past 5-10 years in clinical translational research of thyroid cancer. Diagnostic molecular markers, such as RET-PTC, RAS, and BRAFV600E mutations; galectin 3; and a new gene expression classifier, are outstanding examples that have improved diagnosis of thyroid nodules. BRAF mutation is a prognostic genetic marker that has improved risk stratification and hence tailored management of patients with thyroid cancer, including those with conventionally low risks. Novel molecular-targeted treatments hold great promise for radioiodine-refractory and surgically inoperable thyroid cancers as shown in clinical trials; such treatments are likely to become a component of the standard treatment regimen for patients with thyroid cancer in the near future. These novel molecular-based management strategies for thyroid nodules and thyroid cancer are the most exciting developments in this unprecedented era of molecular thyroid-cancer medicine.
UR - http://www.scopus.com/inward/record.url?scp=84875295216&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84875295216&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(13)60109-9
DO - 10.1016/S0140-6736(13)60109-9
M3 - Review article
C2 - 23668556
AN - SCOPUS:84875295216
SN - 0140-6736
VL - 381
SP - 1058
EP - 1069
JO - The Lancet
JF - The Lancet
IS - 9871
ER -